R&D | Cutting-edge science and innovative research

News

Pharvaris plans filings for HAE drug after pivotal trial win

Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.

News

It turns out COPD may be a laughing matter after all

Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.

News

Novartis falls sharply on another major R&D setback

Novartis has suffered another pipeline blow, this time involving its highly anticipated neuromuscular disease therapy del-desiran.

News

Pharma body sees 'green shoots' in UK investment

The UK is starting to benefit from a "real partnership" between pharma and government, reversing years of diminishing investment, says the ABPI.

News

UK's Claret Capital raises €575m for European biotechs

London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising €575m for "Europe's boldest innovators."

News

Man and woman AI heads - representation concept

FDA doubles down on its push into AI

The FDA has revealed the latest element in its adoption of AI, an agentic AI platform that agency staffers can use to streamline complex tasks.

News

Female HCP talks to female patient sat on examination table

Slow recruitment still hitting UK trials, says pharma

Despite efforts to improve the environment for UK clinical trials, the sector is still facing headwinds like low recruitment rates and rising costs.

R&D

pharmaphorum podcast Episode 221, Sandeep Kulkarni, Tourmaline Bio

On inflammation, heart health, and GLP-1 possibilities, with...

Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Pharvaris plans filings for HAE drug after pivotal trial win

Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.

News

It turns out COPD may be a laughing matter after all

Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Press Releases

Partner Content

Navigating Change: Key Industry Insights at PHARMAP 2026

PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor

Views & Analysis

R&D

Back to basics: X-ray inspection in pharmaceutical and medic...

In pharma manufacturing, x-ray inspection supports a range of quality control processes.

R&D

Decarbonising respiratory care requires a new kind of generi...

Generics manufacturers have long played a critical role in supporting the sustainability of the NHS, delivering affordable medicines at scale, expanding patient access, and helping healthca

R&D

Why the future of eSource starts with the research site

Capturing data digitally at source can significantly reduce the workflow for sites, yet, implementing it across studies has been rather unattainable.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

CAMP4 on a new class of ASO in gene under expression

CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study

Video

R&D

two healthcare professionals looking at chart

Sponsored

Decentralisation by design: Bringing the trial closer withou...

In the third episode of the IQVIA-sponsored PSCS leadership video series, Sinead Callinan, Head of Patient Centred Delivery, discusses DCTs.

R&D

Sponsored

Patient population first: the strategy behind country decisi...

R&D

Sponsored

IQVIA on reducing complexity and workload for clinical trial...

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

Event

Partner Content

4th Cell Therapy for Autoimmune Disease Summit

Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access

Event

Partner Content

10th Complement-Based Drug Development Summit

Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications

Event

Partner Content

Better Antifibrotic Decisions Through Cross-Organ Insights

The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development

Partner Content

Event

Partner Content

4th Cell Therapy for Autoimmune Disease Summit

Developers are racing to overcome challenges around safety, scalability, durability of response, and patient access

Event

Partner Content

10th Complement-Based Drug Development Summit

Uniting leaders pioneering complement-targeted therapies across ophthalmology, neurodegeneration, nephrology, oncology and autoimmune indications

Event

Partner Content

10th Dermatology Drug Development Summit

The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflam

Debates & Insight

Event

Partner Content

World Novel Drug Discovery Summit South Korea

Korea’s First Industry Forum Driving Best-in-Class Discovery for Next-Generation Modalities

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Debates & Insight

Editor's Picks